clinical trial · NCT05702034
A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE
Janssen Research & Development, LLC·phase3·active not recruiting·n = 12,532
Ischemic Stroke; Ischemic Attack, TransientMilvexianPlacebo
brief summary
The purpose of this study is to evaluate whether milvexian compared to placebo reduce the risk of recurrent ischemic stroke.
started
Feb 15, 2023
primary completion
Nov 11, 2026
completion
Dec 9, 2026
last updated
Jul 6, 2026
official title
A Phase 3, Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Study to Demonstrate the Efficacy and Safety of Milvexian, an Oral Factor XIa Inhibitor, for Stroke Prevention After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol